Predictors of failure of fish-oil therapy for intestinal failure-associated liver disease in children.

ABSTRACT:

Background

Parenteral fish-oil (FO) therapy is a safe and effective treatment for intestinal failure-associated liver disease (IFALD). Patients whose cholestasis does not resolve with FO may progress to end-stage liver disease.

Objective

We sought to identify factors associated with the failure of FO therapy in treating IFALD to guide prognostication and referral guidelines.

Design

Prospectively collected data for patients treated with FO at Boston Children's Hospital from 2004 to 2014 were retrospectively reviewed. Resolution of cholestasis was defined as sustained direct bilirubin (DB) <2 mg/dL, and treatment failure as liver transplantation or death while DB was >2 mg/dL as of July 2015. Demographics, laboratory values, and medical history at FO therapy initiation

SUBMITTER: Nandivada P 

PROVIDER: S-EPMC4997303 | biostudies-literature | 2016 Sep

REPOSITORIES: biostudies-literature